Evaluation of cellular immune response and biosafety of SV40 virus-like particle in tumor immunotherapy Authors: Ting He, Ruoxuan Hei, Chong Liu, Huiping Wang, Zhaowei Gao, Ke Dong, Juan Zhang Published: 2025 ABSTRACT AbstractVirus-like particle (VLP) holds great promise for applications in vaccines and tumor immunotherapy. However, their clinical translation has been limited by a lack of comprehensive in vivo studies on immune responses and antigenic toxicity. In this study, we systematically evaluated the efficacy and safety of VLP as immunological agents. We administered Simian Virus 40 (SV40) VLP through subcutaneous injection and analyzed their effects on immune cell populations in key organs. In vivo imaging of mice demonstrated the migration of SV40 VLP between lymph nodes. Flow cytometry revealed that SV40 VLP significantly increased the numbers of CD4+ T cells and NK cells in the spleen, along with elevated levels of CD4+ T cells in mesenteric lymph nodes. Moreover, SV40 VLP did not significantly affect immune cell populations in the lungs, liver, or kidneys, nor did they alter blood biochemistry or coagulation parameters. Although SV40 VLP alone did not exhibit tumor-treating effects, in vitro imaging suggest that SV40 VLP can target tumor tissues and and quantitative analysis showed SV40 VLP significantly increased TNF-α expression in spleen. These findings suggest that SV40 VLP represent a promising tumor immunotherapy vector with potential for further modification.Graphical Abstract Introduction Virus-like particles are three-dimensional protein structures formed by the reversible self-assembly of capsid proteins of viruses, either in vivo or in vitro [1–3]. VLP cannot infect hosts because they do not contain genetic material [4, 5], making them widely used in drug delivery [6], biosensing [7], diagnostics [8] and other applications [9]. The outer surface proteins of VLP are similar to the capsid proteins of viruses, thereby can induce the immune system to produce an antibody response [10]. This characteristic gives VLP significant potential for use in vaccine development [11] and tumor immunotherapy [12]. Although research interest based on VLP within the field of biomedicine continues to grow [13–15], the immune response and biosafety of VLP in the biological systems have not been fully elucidated. Therefore, there is an urgent need to investigate the cellular immune response and biosafety of VLP in vivo, particularly in major organs. VLP come in various shapes and range in size from 20 nm to 200 nm. Studies have shown that VLP can be passively drained to the subcapsular sinus of lymph nodes through lymphatic vessels, where they are recognized and ingested by dendritic cells (DC). Then these VLP are presented via major histocompatibility complexes (MHC) to activate T cell-mediated immune responses [16, 17]. Additionally, VLP can also promote the maturation of DC and stimulate the secretion of pro-inflammatory factors and chemokines, which helps mobilize more antigen-presenting cells to activate immune response [18]. For instance, engineered glycan-costumed VLP can reprogram DC and significantly inhibit tumor growth, as well as the reintroduced cancer cells [19]. And recently, Yang et al. reported a phage MS2-derived VLP-based nanotube hydrogel can induce T cell responses, leading to a dramatic increase in the production of Granzyme B and TNF-α in lymphocytes of spleen [20]. Therefore, the considerable potential of VLP in tumor immunotherapy should not be overlooked. In addition, VLP are easily modified through bioengineering [21, 22], have low production costs [23], and exhibit good stability [24], making them highly favored in the field of vaccine development. VLP-based vaccines can be enhanced immunogenicity and protective efficacy through reformation. Young-Tae Lee et al. engineered Sindbis-virus glycoprotein exhibited VLP with mRNA packaging, which could protect the mice from infections with SARS-CoV-2 or herpes simplex virus type 1 [25]. Furthermore, VLP can be engineered to carry multiple antigens for improving vaccine coverage. Jingdi Pan et al. constructed multivalent epitope-presenting VLP vaccine with broad protection against divergent influenza A and B viruses [26]. However, among these studies, there has been relatively little focus on the biosafety of VLP, especially regarding their cellular immune response and potential antigenic toxicity in major organs. The natural capsid of simian virus 40 (SV40) is composed of three major structural proteins: VP1, VP2, and VP3. Therein, the main capsid protein VP1 can self-assemble into an icosahedral virus-like particle in vitro [27–30]. SV40 VLP is frequently used as a model due to their advantages of easy surface functionalization, biocompatibility, and biodegradability [31, 32]. In this work, we investigated the influence of SV40 VLP on the immune cells quantity in major organs based on tumor immunotherapy. In vivo imaging revealed that SV40 VLP remained in the inguinal region one day after injection and significantly enriched in the inguinal lymph nodes for up to 5 days. Furthermore, we observed a significant increase in the number of CD4+ T cells and NK cells in the spleen, along with a rise of CD4+ T in the mesenteric lymph nodes. It indicated that SV40 VLP can migrate via lymphatic drainage and activate cellular immunity. Most importantly, SV40 VLP did not increase the number of immune cells in the lungs, liver, or kidneys, and blood biochemistry and coagulation function remained normal after multiple subcutaneous injections. This indicates the low antigenic toxicity and favorable biosafety profile of SV40 VLP. Although SV40 VLP failed in the lung cancer tumor suppression, the significant tumor-targeted enrichment and the increase of TNF-α in spleen suggest that SV40 VLP is a promising protein nanoparticle worthy of optimization and modification. Our study establishes a theoretical foundation for the clinical transformation of VLP in immunotherapy application, further emphasizing the significant potential of SV40 VLP in clinical settings. Materials and methods Materials Rosstta-PET32a-5hcVP1 strain was provided by professor Feng Li, fluorescent dye Alexa 647 was purchased from Invitrogen (OR, USA), APC/Cy7 anti-mouse CD3, PE-Cy7 anti-mouse CD4, PE anti-mouse CD8, FITC anti-mouse CD45, APC/Cy7 anti-mouse CD19, Pe-Cy7 anti-mouse CD11b, FITC anti-mouse CD11c, PE anti-mouse NK1.1, PE anti-mouse MHC2 are all purchased from 4A-BIOTECH. Matrigel (Cultrex Pathclear BM) was purchased from R&D (USA). Lymphocyte Separation Kit and RIPA lysis buffer was purchased from Beyotime Biotechnology (Shanghai, China). Mouse TNF-alpha High Sensitivity ELISA Kit (RK04875) was purchased from ABclonal Biotechnology Co., Ltd. (Wuhan, China). Cell and cell culture Murine lung cancer cell lines Lewis were obtained from Procell Life Science & Technology Co., Ltd. (WuHan, China). Cells were maintained in DMEM supplemented with fetal bovine serum and 1% penicillin/streptomycin, cultured at 37 °C with 5% CO2. Animals 6–8 weeks old of C57BL/6 mice were bought from the Experimental Animal Center of the Fourth Military Medical University (Xi’an, China). Animal experiments were performed with the Guidelines for the Care and Use of Research Animals of the Institutional Animal Ethical Committee of Fourth Military Medical University. Expression of SV40 Capsid Protein VP1 Rosstta-PET32a-5hcVP1 was cultured in 5 mL of LB medium containing ampicillin and chloramphenicol at 37 °C and 220 rpm for 9 h, then transferred to 500 mL of LB medium at the same temperature and speed, and cultured for an additional 4 hours until the OD600 reached approximately 0.6. Afterward, IPTG (1 mM) was added to induce the protein expression at 25 °C and 160 rpm for 12 h. The bacteria were then harvested and lysed using ultrasonication. After centrifugation at 4 °C and 10,000 rpm for 30 min (using a Sorvall lynx 6000 Thermo), the supernatant underwent 80% ammonium sulfate precipitation. The precipitate was then centrifuged, and the entire precipitation was re-dissolved in the assembly buffer (1 M NaCl, 10 mM Tris-HCl, 1 mM CaCl2, 5% glycerol) with magnetic stirring overnight. Then the mixture was centrifuged again at 4 °C and 50,000 rpm (using an OPTIMA L-100XP Beckman) for 1 h to collect the precipitate, which was then resuspended in the depolymerization buffer (10 mM Tris-HCl, 200 mM NaCl, 10 mM EDTA, 5% glycerol) and centrifuged once more at 5000 rpm at 4 °C for 1 h. The supernatant contained SV40 VP1. Self-assembly and purification of SV40 VLP The concentration of SV40 VP1 was determined using gray analysis based on SDS-PAGE. Then 0.5 mg/mL of SV40 VP1(10 mM Tris-HCl, 200 mM NaCl, 10 mM EDTA, 5% glycerol, pH 8.9) was dialyzed (using an 8–14 KDa cutoff) in pre-cooled assembly buffer (1 M NaCl, 10 mM Tris-HCl, 1 mM CaCl2, 5% glycerol, pH 7.2) and stirred at 4 °C for at least 36 h. After dialysis, the SV40 VP1 solution was concentrated to 10 mL for sucrose density gradient centrifugation at 4 °C and 38,000 rpm for 4 hours. Then the self-assembled SV40 VLP were in the 4th to 5th layers of sucrose gradient. The purified SV40 VLP was then dialyzed against PBS to remove sucrose and concentration was measured for further use. Transmission electron microscopy Samples of SV40 VLP were adsorbed to carbon-coated copper grids for 5 min and stained with 2% phosphotungstic acid for 3 min. The grid was dried at room temperature and observed on a Thermofisher Talos L120C transmission electron microscope at 120 kV with an Olympus camera. Dynamic Light Scattering Measurement of SV40 VLP Particle Size SV40 VLP (0.5 mg/mL, 200 μL) in PBS was loaded into a micro cell. Then the hydrodynamic diameter was measured by a Malvern Nanosizer Nano ZS DLS instrument (UK) with 10% power and sample was run three times. Lung cancer model and animal experiments Before tumor implantation, SV40 VLP was administered subcutaneously twice via the left lower inguinal region of about eight-week old female C57BL/6 mice. Then murine lung cancer Lewis cells were subcutaneously inoculated on the right hind limbs (1 × 106 cells in 100 μL Matrigel). After the tumors grew for 4 days, 80 μg of SV40 VLP was repeated injected through the left lower inguinal region for every 4 days and total 6 times. During the entire drug administration period, the tumor size was recorded with a vernier caliper. The tumor volume = 0.5 × length × width2. After the sixth administration, animals were anesthetized with isoflurane and then euthanized. The main organs, lymphoid tissues and tumors were excised for imaging, flow cytometry and immunohistochemical analysis. In vivo imaging following SV40 VLP injection SV40 VLP were labeled with Alexa 647 fluorescent dye during the last injection, and the mice were imaged at 1 and 5 days post-injection after isoflurane anesthesia using an IVIS Spectrum In vivo Imaging System from Korea (with 650 nm excitation and 680 emission filters). Biodistribution of SV40 VLP: subcutaneous vs. intravenous injection Male C57BL/6 mice were administered a dose of 100 μg of Alexa 647 labeled SV40 VLP via either subcutaneous (inguinal region) or tail vein injection. At 24 h post-injection, the mice were anesthetized with isoflurane and euthanized. Major organs, including the heart, liver, spleen, lungs, and kidneys, were then harvested and rinsed with cold PBS. The biodistribution differences of VLP between the two injection routes were compared using a multimodal in vivo imaging system (AniView100 DXA, Guangzhou Biolight Biotechnology Co., Ltd.). Flow cytometry analysis The activation of immune cells in major organs was analyzed after multiple injections using flow cytometry. The axillary and inguinal lymph nodes, mesenteric lymph nodes, lung, liver, spleen and kidney were ground to prepare single-cell suspensions. Red blood cells were lysed using an NH4Cl solution and centrifuged at 4000 rpm for 5 min to collect the remaining cells. After resuspension, the cells were labeled with FITC-conjugated anti-mouse CD45, APC-Cy7-conjugated anti-mouse CD3, PE-Cy7-conjugated anti-mouse CD4 and PE-conjugated anti-mouse CD8 to identify CD4+ and CD8+ T cells. To identify NK and B cells, 100 μL of single-cell suspension was labeled with FITC-conjugated anti-mouse CD45, PE-conjugated anti-mouse NK1.1 and APC-Cy7-conjugated anti-mouse CD19 antibodies. Dendritic cells were labeled with APC-conjugated anti-mouse CD11c antibody, and FITC-conjugated anti-mouse CD11b. After mixing the cells with antibodies, the mixture was incubated for 30 min in the dark. The samples were then centrifuged at 4000 rpm for 5 min, the supernatant was discarded, and cells were resuspended in saline. Finally, the samples were analyzed using a flow cytometry (BD Company, USA). CD4+T cells, CD8+T cells, NK cells, B cells and DC were gated using the following markers: CD45+CD3+CD4+, CD45+CD3+CD8+, CD45+NK1.1+, CD45+CD19+ and CD11c+CD11b+. Blood biochemical assays and blood coagulation test 80 μg of SV40 VLP were administered for six injections to each mouse, after which blood was collected through cardiac puncture following euthanasia. Serum was separated by centrifugation at 3000 g using EDTA as an anticoagulant. Serum biochemical parameters, including blood and urine nitrogen (BUN), alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST), total bilirubin (TB) were measured using an automatic AU5800 analyzer (Beckman, USA). Prothrombin time (PT) and Prothrombin activity (PTA) were determined using an automatic coagulation CP2000 analyzer (Coapresta® 2000, Japan) following the manufacturer’s protocol. Western Blotting (WB) analysis of the anti-VLP antibody levels After 8 dose treatment of SV40 VLP based on subcutaneous injection, the mice were anesthetized and euthanized. Blood was collected by cardiac puncture immediately and blood was centrifuged at 3000 rpm for 10 min. The supernatant was separated to prepare serum for WB analysis. Then same amount of SV40 VLP was subjected to SDS-PAGE and transferred to PVDF membrane. The serum of each mouse was separately incubated with the PVFD membrane as a primary antibody (4 mice per group), and the secondary antibody was HRP-labeled goat anti-mouse IgG. Quantitative determination of TNF-α Levels in the Spleen Both VLP and PBS were administered via subcutaneous injection into the right inguinal region every other day for a total of six injections. Two days after the final injection, the mice were euthanized, and the spleens were aseptically harvested. The spleens were gently homogenized to generate single-cell suspensions. Splenic lymphocytes were then isolated using a lymphocyte separation medium. Total protein was extracted from the lymphocytes with RIPA lysis buffer. The protein concentration was quantified using a Bradford assay kit and adjusted to a uniform concentration of 3 mg/ml. Finally, the concentration of TNF-α was quantitatively measured according to the manufacturer’s instructions of an ELISA kit from ABclonal. Statistical analyses All statistical analyses were conducted using GraphPad Prism 9, and the data are presented as mean ± standard deviations (SD). Student’s t-test was employed for statistical analyses. The threshold of statistical significance was set at P-values < 0.05. Results and discussion Characterization of SV40 VLP SV40 capsid protein VP1 was expressed by Escherichia coli, and the VP1 pentamer was obtained through ammonium sulfate precipitation followed by ultracentrifugation. VP1 has a molecular weight of 41 kDa, and SDS-PAGE analysis revealed that the purity of the VP1 was greater than 95% (Fig. 1A). The purified VP1 pentamer can self-assemble into an icosahedral cage structure upon induction with calcium ions and changes in pH in vitro. We isolated the assembled SV40 VLP using sucrose density gradient centrifuge. Transmission electron microscope (TEM) image demonstrated that the SV40 VLP were homogenized and well-dispersed (Fig. 1B). Dynamic light scattering measurements showed that the particle size of SV40 VLP was approximately 24.36 nm. (Fig. 1C). Studies have shown that the antigenicity of nanoparticles is significantly influenced by their size [33], with smaller nanoparticles being transported more rapidly than larger ones [34]. Consequently, SV40 VLP possesses a natural advantage in stimulating immune response. Characterization of SV40 VLP. A SDS-PAGE characterization of the purified SV40 VLP. M: protein marker. B Transmission electron microscopy image of SV40 VLP. Scale bars: 100 nm. C Hydrodynamic diameter of SV40 VLP analysed by Dynamic light scattering In vivo imaging of SV40 VLP after subcutaneous inguinal injection Determining whether SV40 VLP can drain to lymph nodes is crucial for their development as immune agents. We covalently labeled SV40 VLP with the fluorescent reagent Alaxe 647 and subsequently subcutaneously injected the labeled VLP into the left lower groin of mice (Fig. 2A). In vivo imaging revealed a strong fluorescence signal from the SV40 VLP in inguinal lymph node 1 (LN1) one day after injection (Fig. 2B), and the signal persisted until the day five post-injection (Fig. 2C). Our observations differ from previous findings using the J8-VLP formulation [35], in which subcutaneous administration resulted in rapid clearance within 24 h and no detectable fluorescent signal. This contrast underscores a potentially distinctive feature of the SV40 VLP platform, the in vivo stability. In vivo distribution of SV40 VLP. A Illustration of lymph node sites and SV40 VLP injection site. B, C In vivo fluorescence imaging of axillary and inguinal lymph nodes after 1 day (B) or 5 days (C) subcutaneous injection of SV40 VLP in mice. D Fluorescence intensity measurement of axillary and inguinal lymph based on fluorescence image of SV40 VLP in (C) Furthermore, fluorescence signals of SV40 VLP began to appear at inguinal lymph nodes on the 5th day after injection (Fig. 2D). This suggests that SV40 VLP can migrate from inguinal lymph node to contralateral and axillary lymph nodes (LN2), indicating that the VLP can drain to other lymph nodes due to their nanoscale size and stability. Enhancing immunogenicity relies on strategies that prolong antigen depot duration and promote lymphatic trafficking. For example, hepatitis B surface antigen VLP with lipid nanoparticle have been shown to extend antigen retention at the injection site for up to 72 h. In contrast to the short-lived exposure formulation of aluminum-VLP, this approach elicits a stronger cellular immune response [36]. Our observations indicate that SV40 VLP possess the fundamental conditions necessary for interacting with immune cells. However, more efficient lymphatic migration of SV40 VLPs may necessitate the incorporation of exogenous components. For instance, VLPs conjugated with BSA or iRGD demonstrated improved trafficking to lymph nodes compared to unmodified VLPs in a mouse model [37]. Su et al. reported that P22 VLP expressing cell-penetrating peptides could enhance the tissue accumulation and retention [38]. This finding suggests that the introduction of functional peptides represents an effective strategy for improving VLP retention in tissues. Change in immune cell quantity in multiple organs induced by SV40 VLP SV40 VLP can drain to the contralateral lymph nodes, which is essential for antigen presentation and T cell activation. Therefore, we next analyzed the cellular immune response to SV40 VLP following repeated administration. Flow cytometry revealed that SV40 VLP significantly elevated the number of CD4+T cells in mesenteric lymph nodes (Fig. 3A, B), while CD8 + T cells had no change. Liang et al. reported that encapsulating the immunostimulatory CpG within the lumen of HBC VLPs only marginally increased CD4+ T cells, without eliciting a significant CD8+ T cell response. A substantial T cell activation was achieved only when HBC VLPs were surface-conjugated with an antibody targeting the immune checkpoint molecule B7-H3 [39]. These findings suggest that naked VLPs alone induce a limited immune response. SV40 VLP-activated cells in the spleen and lymph nodes. (A, B) Flow cytometry analysis (A) and quantification (B) of CD4T cell proliferation in mesenteric lymph nodes after repeated SV40 VLP injections; (C, D) Flow cytometry analysis (C) and quantification (D) of NK cell activation in the spleen following repeated SV40 VLP injection; (E, F) Flow cytometry analysis (E) and quantification (F) of CD4 T cell activation in the spleen after repeated SV40 VLP injection. Gating strategies were shown in Figs. S2, S3 Nevertheless, we also examined changes in immune cell populations in the spleen following SV40 VLP administration. We observed that SV40 VLP significantly increased the number of NK cells (Fig. 3C, D) and CD4+T cells in the spleen (Fig. 3E, F). Theoretically, NK cells can directly kill tumor cells [40, 41], while CD4+T cells indirectly or directly kill tumor through MHCⅡ molecules on antigen-presenting cells [42–45], respectively. Therefore, our results reaffirm the significant potential of SV40 VLP as a novel tumor immunotherapy agent. However, similar to the immune response observed in lymph nodes, no significant increase in CD8+ T cells was significant in the spleen (Fig. S1). These results suggest that there remains considerable potential to further optimize SV40 VLPs for enhanced immunogenicity. For example, future modifications could include the incorporation of polyarginine/cysteine-tagged antigens to promote [46], or the use of novel inorganic materials as adjuvants to improve the activation efficiency of both CD4⁺ and CD8⁺ T cells [47]. Owing to the absence of a viral genome and infectivity, VLPs are considered highly safe, making them promising platforms for vaccines [48, 49], drug delivery [50], and immunotherapy fields [51]. However, the immune storm induced by immunotherapy agents is a limitation for their clinical translation [52–54]. Therefore, we further investigated the change of immune cell quantity in the lung, liver and kidney following SV40 VLP injections. Flow cytometry analysis revealed that subcutaneous injection of SV40 VLP did not influence CD4+ T cells, CD8+T cells, B cells, NK cells or DCs in the liver (Fig. 4A), lung (Fig. 4B) or kidney (Fig. 4C). Taken together, SV40 VLP stimulates the proliferation of T cells and NK cells in the lymph nodes and spleen, without affecting the cell populations in the lungs, liver, or kidneys. This property avoids systemic immune storm and ensures the safety of SV40 VLP use as immune formulations. Immunity disturbance of SV40 VLP in major organs. (A, C)Flow cytometry analysis of the changes of CD4+T cells,CD8+T cells, NK cells, B cells and DCs in single-cell suspensions from the liver (A), lung (B) and kidney (C) after repeated SV40 VLPinjections. Statistical analysis showed no significant (ns) differences in immune cell activation among the three organs Next, we evaluated the blood safety of SV40 VLP after multiple subcutaneous injections. Prothrombin time (PT) and prothrombin activity (PTA) tests indicated that SV40 VLP do not significantly affect coagulation function (Fig. 5A). Additionally, SV40 VLP did not cause notable changes in the levels of various blood biochemical indicators, including blood urea nitrogen (BUN) (Fig. 5B), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TB) (Fig. 5C). These findings demonstrate that SV40 VLP have no apparent adverse effects and exhibit good biocompatibility, which is crucial for their application in immunotherapy in vivo. Biosafety assessment of SV40 VLP. A Blood coagulation tests of SV40 VLP. Prothrombin time (PT) is the duration required for blood to clot in vitro and primarily reflects the function of the exogenous coagulation pathway. A prolonged PT may indicate coagulation factor deficiency or the influence of exogenous material. Prothrombin activity (PTA) is a sensitive index for assessing the severity and prognosis of hepatocyte necrosis with a normal range of 75% to 100%. PTA values below 40% can indicate a diagnosis of acute severe hepatitis. B, C Blood biochemistry evaluation of SV40 VLP, (B) Blood urea nitrogen (BUN), which belongs to renal function testing, (C) Liver function test includes alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TB). With the exception during pregnancy, elevations in ALT, AST, ALP and TB are generally associated with the degree of hepatocyte injury or hepatobiliary disease Given these findings, can SV40 VLP be used as an agent to inhibit tumor growth? We administered SV40 VLP twice prior to subcutaneously inoculating Lewis lung carcinoma cells, followed by six additional VLP injections once every four days (Fig. 6A). After treatment, we first examined the distribution of SV40 VLP in tumor-bearing mice. Imaging results revealed no significant accumulation of VLPs in the heart, spleen, or lung compared to the PBS group (Fig. 6B), whereas a slightly higher level of VLP accumulation was observed in the kidneys compared to the PBS group (Fig. 6C). This suggests that subcutaneously administered SV40 VLP may be primarily cleared through renal metabolism. Response of SV40 VLP in lung cancer tumor-bearing mouse models. A The experimental timeline; (B) Ex vivo fluorescence imaging of heart, liver, spleen, lungs and kidneys following a total of eight subcutaneous injections of SV40 VLP in mice. C Quantification of fluorescence intensity in heart, liver, spleen, lung and kidneys following repeated injections of SV40 VLP in mice, (n = 5); (D) Ex vivo fluorescence imaging of tumor after repeated SV40 VLP injections; (E) Fluorescence intensity measurement of the tumors in (D), (n = 5); (F) Ex vivo fluorescence imaging of inguinal (LN1 and LN2) and axillary (LN3 and LN4) lymph nodes after endpoint of therapy, the lymph node sites denoted by LN1, LN2, LN3 and LN4 are identical to those depicted in the schematic diagram of Fig. 2A. G Fluorescence intensity measurement of axillary and inguinal lymph based on ex vivo fluorescence image in (F). H Western blot analysis of the anti-VLP antibody levels after repeated dosing. Serum samples from each mouse treated with SV40 VLP were used as primary antibodies. I Densitometric analysis of SV40 VLP antibody levels based on the western blot data in (H), n = 4. J Body weight changes following a total of eight subcutaneous injections of SV40 VLP in mice. K Immunohistochemistry staining of TNF-α in the spleen of mice after repeated SV40 VLP administrations. Brown staining indicates positive TNF-α expression. L Tumor growth curves in mice injected with PBS or SV40 VLP, (n = 8). Data are shown as means ± SD Despite a visual impression of slight liver fluorescence in the VLP group, quantitative analysis across multiple mice confirmed no significant difference from PBS control (Fig. 6C), which also reflects the relatively high autofluorescence of liver tissue compared to other organs. Additionally, we confirmed that subcutaneous injection results in considerably lower liver accumulation of VLPs compared to intravenous injection (Fig. S4). Notably, tumor tissues exhibited a stronger fluorescence signal in the VLP group than in the PBS group (Fig. 6D, E), indicating that SV40 VLP may preferentially migrate to tumor tissues via lymphatic vessels. However, at the conclusion of the treatment, ex vivo imaging of the inguinal and axillary lymph nodes revealed that (Fig. 6F, G), with the exception of inguinal lymph node site 1 (LN1), which exhibited a significant difference in the VLP injection group, no significant differences in VLP enrichment were observed at the other three lymph node sites (LN2, LN3 and LN4). Western blot analysis also revealed a distinct SV40 VLP-specific antibody response in serum following repeated injections (Fig. 6H and I). The weight monitoring process indicated that, although a significant weight loss on the 18th day of VLP injection, the weight eventually returned to a level comparable to that of the control group (Fig. 6J). The biological safety of VLP was clarified once again even function with cell response. Immunohistochemistry staining revealed a modest increase in TNF-α expression in the spleen following SV40 VLP treatment (Fig. 6K). Consistent with this observation, ELISA quantification further demonstrated a significantly higher level of TNF-α in the spleens of the VLP-treated group (2.28 pg/mL) compared to the PBS control group (0.87 pg/mL) (Fig. S5). This finding is in line with previous reports showing that mannoside-engineered Qβ bacteriophage VLPs can enhance the proportion of TNF-α+CD4⁺ T cells [55]. As TNF-α is a key cytokine involved in T helper type 1 (TH1) responses, effective T helper type 1 (TH1)-like immune response is necessary for cancer treatment [56]. Notably, tumor growth in the SV40 VLP-treated mice was slower than in the PBS group up to day 31 after tumor implantation (Fig. 6L). However, the tumor was not completely suppressed by the end of the dosing regimen, which may be attributed to the lack of increased CD8+ T cell activation in the spleen or lymph nodes. Our results indicate that while VLP can function as delivery vehicles for tumor immunotherapy, their administration alone is insufficient to elicit specific tumor suppression or robust immune responses. To fully exploit the therapeutic potential of SV40 VLP in cancer treatment, it will be necessary to integrate this approach with complementary strategies, such as incorporating a therapeutic agent that can synergize with the VLP to enhance antitumor efficacy, or embedding tumor-specific antigens and immunostimulatory adjuvants within the VLP structure to reduce immunosuppression and promote T lymphocyte infiltration into tumor sites. Conclusion SV40 VLP, formed from the main capsid protein VP1, is easy to assemble and disassemble, can be mass-produced and bioengineered, and serves as an excellent model for studying virus-like particles. It is known that various sources, structures and shapes of VLP can elicit different immune responses. Our results demonstrated that mammalian-derived SV40 VLP could effectively migrate to lymph nodes and significantly increase the numbers of CD4+ T cells and NK cells in the spleen, as well as CD4+ T cells in mesenteric lymph nodes. Most importantly, SV40 VLP did not induce the proliferation of immune cells in the lungs, liver, or kidneys, nor did they cause blood index disorders, demonstrating their biostability and safety, which is the essential prerequisite for its clinical application. The main capsid protein SV40 VP1 exhibits a high tolerance for protein fusion or modification. Both the N-terminal region and the DE-loop as well as H1 loop of VP1 can be engineered to carry amino acids or even entire proteins without impairing VLP assembly. This allows for the incorporation of molecules such as PD-1 antibodies to counteract immune suppression [57], or IL-33 to promote the formation of tertiary lymphoid structures [58], or toll-like receptor agonists like resiquimod (R848) to enhance antitumor immune responses [59]. Although our results showed that VLP alone did not inhibit lung tumor growth, it can stimulate cellular immune responses in the spleen and lymph nodes. This suggests that, with rational modifications, SV40 VLP could be developed into effective novel strategies for tumor immunotherapy. Overall, our findings indicate that SV40 VLP have broad potential for immunotherapeutic applications, supported by their moderate organ-specific immune activation and favorable biosafety profile. Supplementary information Supporting information Acknowledgements This research was supported by “Phoenix Introduction Plan” Talent Startover Project of Tangdu Hospital, Fourth Military Medical University (2021YFJH014), and the Youth Independent Innovation Science Fund of Tangdu Hospital (2023CTDQN028). We thank Professor Feng Li from the Wuhan Institute of Virology, Chinese Academy of Sciences, for providing the Rosstta-PET32a-5hcVP1 strain. We also thank Anna Du and Pei Zhang from the Institutional Center for Shared Technologies and Facilities of Wuhan Institute of Virology for their technical support in transmission electron microscopy. Author contributions JZ, KD, ZWG, and TH proposed the concept, designed the experiment, and analyzed data; TH carried out most of the experiments; RXH and CL provided help for single-cell suspension preparation and FCM experiments. HPW provided help for some of the in vivo experiments; TH and JZ wrote the manuscript. All of the authors approved the final version of the manuscript. Compliance with ethical standards Conflict of interest The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Zhaowei Gao, Email: gaozhaowei1@126.com. Ke Dong, Email: tdjyk3@fmmu.edu.cn. Juan Zhang, Email: zjerjy@126.com. Supplementary information The online version contains supplementary material available at 10.1007/s10856-025-06986-0. References Associated Data Supplementary Materials Supporting information